Hydroxymesterone
Hydroxymesterone (typically the 11-beta-hydroxy analogue of methyltestosterone, closely related to fluoxymesterone without the 9-fluoro) is a 17-alpha-methylated oral androgen. It is strongly androgenic with limited aromatisation, and shares the hepatotoxicity and suppression of the fluoxymesterone family. Human data are sparse and largely historical.
01 Overview
Hydroxymesterone sits in the halotestin (fluoxymesterone) structural family: 17-alpha-methylated with an 11-hydroxy substitution. The result is a potent, dry androgen used historically in small numbers of clinical contexts and, non-medically, for strength and aggression rather than size.
Like its fluorinated cousin it is markedly hepatotoxic and suppressive. It does not deliver much mass; the appeal is a hard, strength-oriented effect with pronounced CNS androgenic activity.
02 Mechanism
Androgen-receptor agonist in the fluoxymesterone family; 17-alpha-methyl group enables oral activity; 11-hydroxy substitution limits aromatisation.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 10–20 mg/day | Oral | Strength-oriented dosing; no established medical dose. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Strength increaseHalotestin-like strength and aggression. | notable without much mass | Anecdotal | |
| Muscle hardnessDry, hard look without water retention. | visual | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Adverse lipids and blood pressureHDL suppression and raised blood pressure. | Moderate | Common | Observational | |
| HepatotoxicityMarked hepatic strain, as with the fluoxymesterone family. | Severe | Common | Observational | |
| HPTA suppressionSuppresses endogenous testosterone. | Severe | Universal | Observational |